Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 10/20 | 0.51 |
| ▸ | CA2 | P00918 | 10/20 | 0.51 |
| ▸ | CA9 | Q16790 | 10/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA3 | P07451 | 1/20 | 0.51 |
| ▸ | CA4 | P22748 | 1/20 | 0.51 |
| ▸ | CA6 | P23280 | 1/20 | 0.51 |
| ▸ | CA5A | P35218 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.51 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | LPL | P06858 | 3/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17393865 | 0.85 | CA1 (0.47) | CA1CA2CA9CA12CA3 | |
| SCHEMBL17393818 | 0.84 | CA1 (0.47) | CA1CA2CA9CA12CA3 | |
| SCHEMBL1164195 | 0.82 | KDM4E (0.55) | CA1CA2CA9CA12CA3 | |
| SCHEMBL1558127 | 0.82 | CA1 (0.55) | CA1CA2CA9CA12CA3 | |
| SCHEMBL15002400 | 0.81 | CA1 (0.44) | CA1CA2CA9CA12CA3 | |
| SCHEMBL4782876 | 0.81 | CA1 (0.48) | CA1CA2CA9CA12CA3 | |
| SCHEMBL19450354 | 0.80 | CA1 (0.45) | CA1CA2CA9CA12CA3 | |
| SCHEMBL15002399 | 0.80 | CA1 (0.43) | CA1CA2CA9CA12CA3 | |
| SCHEMBL16015086 | 0.80 | BRD4 (0.45) | CA1CA2CA9CA12CA3 | |
| SCHEMBL13268964 | 0.80 | CA1 (0.43) | CA1CA2CA9CA12CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2947084-B1 | FIVE-AND-SIX-MEMBERED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO (CN) | 2020-09-23 | — | — | EP | disclosed |
| US-9745320-B2 | Five-and-six-membered heterocyclic compound, and preparation method, pharmaceutical composition and use thereof | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2017-08-29 | — | — | US | disclosed |
| US-20150336982-A1 | Five-And-Six-Membered Heterocyclic Compound, And Preparation Method, Pharmaceutical Composition And Use Thereof | SHANGHAI CHEMEXPLORER CO., LTD. (CN) | 2015-11-26 | — | — | US | disclosed |
| EP-2947084-A1 | FIVE-AND-SIX-MEMBERED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Chemexplorer Co., Ltd. (CN) | 2015-11-25 | — | — | EP | disclosed |
| WO-2014111037-A1 | FIVE-AND-SIX-MEMBERED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海昀怡健康管理咨询有限公司 (CN) | 2014-07-24 | — | — | WO | disclosed |
| US-8008301-B2 | (2-(S)-Pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-(4'-trifluoromethyl-biphenyl-4-yl)-methanone; treatment of nervous system disorder, obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008301-B2 | (2-(S)-Pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-(4'-trifluoromethyl-biphenyl-4-yl)-methanone; treatment of nervous system disorder, obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008301-B2 | (2-(S)-Pyrrolidin-1-ylmethyl-pyrrolidin-1-yl)-(4'-trifluoromethyl-biphenyl-4-yl)-methanone; treatment of nervous system disorder, obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases | ELI LILLY AND COMPANY (US) | 2011-08-30 | — | — | US | disclosed |
| EP-1530470-B9 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | LILLY CO ELI (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20100048580-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | BEAVERS LISA SELSAM | 2010-02-25 | — | — | US | disclosed |
| US-20070208024-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY | 2007-09-06 | — | — | US | disclosed |
| US-20070208024-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY | 2007-09-06 | — | — | US | disclosed |
| EP-1782810-A2 | Selective estrogen receptor modulators containing a phenylsulfonyl group | Eli Lilly & Company (US) | 2007-05-09 | — | — | EP | disclosed |
| EP-1735278-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20060258670-A1 | New phenylpyridylpiperazine compounds | LES LABORATOIRES SERVIER (FR) | 2006-11-16 | — | — | US | disclosed |
| EP-1721897-A1 | Phenylpyridinylpiperazin derivatives, the process to make them and the pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2006-11-15 | — | — | EP | disclosed |
| US-20060183736-A1 | Selective estrogen receptor modulators containing a phenylsulfonyl group | ELILILLY AND COMPANY | 2006-08-17 | — | — | US | disclosed |
| WO-2005097740-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-10-20 | — | — | WO | disclosed |
| EP-1530470-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | ELI LILLY AND COMPANY (US) | 2005-05-18 | — | — | EP | disclosed |
| WO-2004009086-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP | ELI LILLY AND COMPANY (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258670-A1 | New phenylpyridylpiperazine compounds | HRH4, HRH3, HRH2 | CA1 1851/4885CA2 847/4885CA9 3926/4885 |
| US-20150336982-A1 | Five-And-Six-Membered Heterocyclic Compound, And Preparation Method, Pharmaceutical Composition And Use Thereof | JAK1, JAK2, JAK3 | CA1 3858/4885CA2 3053/4885CA9 1072/4885 |
| US-20070208024-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | HRH3, HRH4, HCRTR1 | CA1 859/4885CA2 1259/4885CA9 2005/4885 |
| US-20100048580-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | HRH3, HRH4, HCRTR1 | CA1 859/4885CA2 1259/4885CA9 2005/4885 |
| US-20060183736-A1 | Selective estrogen receptor modulators containing a phenylsulfonyl group | GPER1, ESR2, ESR1 | CA1 1803/4885CA2 303/4885CA9 1839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.